Acalabrutinib Versus Investigator’s Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results-Reference-Cited by-同舟云学术

Acalabrutinib Versus Investigator’s Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results

Published:2022-11-14 Issue:12 Volume:6 Page:e801
ISSN:2572-9241
Container-title:HemaSphere
language:en
Short-container-title:

Author:

Ghia Paolo,Pluta Andrzej,Wach Małgorzata,Lysak Daniel,Šimkovič Martin,Kriachok Iryna,Illés Árpád,de la Serna Javier,Dolan Sean,Campbell Philip,Musuraca Gerardo,Jacob Abraham,Avery Eric J.,Lee Jae Hoon,Usenko Ganna,Wang Min Hui,Yu Ting,Jurczak Wojciech

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Hematology

Reference16 articles.

1. Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances;Wen;Leukemia,2021

2. Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma;Munir;Am J Hematol,2019

3. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes;Archibald;Ann Hematol.,2021

4. Risk of bleeding complications and atrial fibrillation associated with ibrutinib treatment: a systematic review and meta-analysis;Pellegrini;Crit Rev Oncol Hematol.,2021

5. Ibrutinib increases the risk of hypertension and atrial fibrillation: systematic review and meta-analysis;Caldeira;PLoS One.,2019

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Acalabrutinib in Chinese patients with relapsed/refractory chronic lymphocytic leukemia: Primary analysis from an open-label, multicenter phase 1/2 trial;Annals of Hematology;2024-09-14

2. Pharmacological management of chronic lymphocytic leukemia: current and emerging therapies;Expert Opinion on Pharmacotherapy;2024-09-08

3. Utilizing risk factors to guide treatment decisions in chronic lymphocytic leukemia;Expert Review of Anticancer Therapy;2024-09-02

4. Severe infections in patients with chronic lymphocytic leukemia included in trials investigating BTK and BCL2 inhibitors;Critical Reviews in Oncology/Hematology;2024-09

5. ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia;Annals of Oncology;2024-09